METHOD FOR TREATMENT OF MALIGNANT NEUROENDOCRINAL TUMOURS OF PANCREAS HEAD WITH METASTASES IN LIVER Russian patent published in 2017 - IPC A61B6/03 A61B17/00 A61N5/02 A61M5/00 A61K31/704 A61K49/18 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention can find application in treatment of malignant neuroendocrine tumours (NET) of the pancreas head (PH). Prior to surgery to remove the primary tumour, selective intraarterial oily chemoembolization of the pancreas head vessels is performed using 0.3 mg/kg of doxorubicin in 6-7 ml of lipidol, of which 1/3 of doxorubicin and 3 ml of lipidol are administered super-selectively into the tumour vessels. Simultaneously, intraarterial oily chemoembolization of blood vessels feeding the liver and NET metastases is performed using 0.4 mg/kg of doxorubicin in 6-7 ml of lipidol. Then, during surgery to remove the primary tumour, radiofrequency ablation (RFA) is also performed in the presence of a single large metastatic lesion or multiple metastases in the liver. After surgery, intraarterial oily chemoembolization of liver metastases is performed, using doxorubicin at a dose of 0.5-0.7 mg/kg in 5-10 ml of lipidol until remission is achieved, under the control of PET with radiopharmaceutical (RP) Ga-68 DOTATATE. If pathological accumulation of RP is detected in the tumour bed at a local relapse or when distant NET metastases are detected, antitumor treatment is conducted. The primary tumour of the pancreas head is removed as a standard pancreatoduodenal resection in isolated neoplasms or in the form of an extended operation with resection of surrounding organs and main vessels, or in the form of extended lymphadenectomy with minimization or absence of surgical influence on intrahepatic metastases. Ga-68 DOTATATE is used at a dose of 1.5 MBq/kg, but not less than 100 MBq per administration.

EFFECT: method provides minimization of surgical treatment traumatism at high treatment efficiency.

3 cl, 2 ex